Venture Global agreed to a new 20-year sales and purchase agreement with Malaysian state-owned energy firm Petronas to secure ...

During his five years in the Navy, Leland Remias encountered a problem many service members know all too well from frequent moves: real estate agent fees. So he created a platform where buyers and ...

Halogen Ventures launches a $30 million fund to invest in early-stage, women-led startups focused on solving the $7.5 ...

The partnership has helped 23 Chicago-area entrepreneurs get zero-interest loans from crowdfunding platform Kiva, and ...

The departing Jarnow helped set up EQT’s venture arm around ten years ago and is best known for gaming investments like Small ...

Earnings Estimate Revisions for Eton Pharmaceuticals This company is expected to earn $0.56 per share for the fiscal year ending December 2025, which represents a year-over-year change of 473.3%.

Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025.

ETON pharma is on its way to dominate the niche ultra-rare disease space. The current owners of orphan drugs, often giant pharma companies, do not have the focus for these tiny drugs, and they are ...

Eton Pharmaceuticals ETON is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.

BURLINGTON, VT, May 04, 2025 (GLOBE NEWSWIRE) -- VENTURE.co Services is proud to announce the launch of VENTURE.co Fund Services, a comprehensive fund administration and transfer agent solution ...

VENTURE.co, a pioneer in the Fin-Tech space for over a decade, integrates the highly effective VENTURE.co application with transfer agent services. VENTURE.co Fund Services is set to redefine the ...

Eton Pharmaceuticals, Inc (Eton), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the submission of a New Drug Application (NDA) ...